Combination Therapy

Towards An Understanding Of The Possible Future Role Of Combining Chemotherapy With Immunotherapy – On The Horizon

There was a study published in the journal Nature that described a promising new combination therapy for the treatment of men with advanced prostate cancers that are non-responsive to chemotherapy. The study is entitled "Immunosuppressive Plasma Cells Impede T-Cell Dependent Immunogenic Chemotherapy." The study was conducted at the University of California, San Diego. Prostate cancers [...]

By Malecare|2017-10-19T10:47:20-04:00May 29th, 2015|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials & Research, Combination Therapy, Immunosuppressive B cells, oxaliplatin, Research, Uncategorized|0 Comments

Prostvac In Combination With Yervoy Yields A Survival Advantage

There is some really exciting news on the horizon around immunotherapy for advanced prostate cancer. Bavarian Nordic, the pharmaseutical company that has, along with the National Cancer Institute (NCI), been running clinical trials on Prostvac has unoffically let it been known that Prostvac when combined with another investigational immunologic therapy, Yervoy, has helped to significantly [...]

By Malecare|2017-10-19T10:47:30-04:00February 24th, 2015|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, immunotherapy, ipilimumab, NCI, On The Horizon, Uncategorized, Yervoy|7 Comments

Radiation Plus Hormone Therapy Prolongs Survival for Older Men with Locally Advanced Prostate Cancer *

It was recently discovered that if hormone therapy (ADT) is added to radiation cancer deaths are lowered by nearly 50 % in men with locally advanced prostate cancer aged 76 to 85 compared to men who only received hormone therapy. Prior studies have shown that 40% of men with aggressive prostate cancers are treated with [...]

By Malecare|2021-11-04T10:13:59-04:00January 22nd, 2015|ADT, Advanced Prostate Cancer, Combination Therapy, Drugs & Treatments, General Information, Hormone Therapy, Radiotherapy, Research, Uncategorized|0 Comments

Updated Overall Survival (OS) Data from a Phase 3 Trial of Ipilimumab (Ipi) vs. Placebo in Men Post Chemotherapy

In a poster presentation at the recent European Society of Medical Oncologists (ESMO) there was a very interesting poster presented updating a phase 3 clinical trial (CA184-043) which evaluated the overall survival (OS) with radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. This trial did not meet its endpoint [...]

By Malecare|2017-10-19T10:47:45-04:00October 23rd, 2014|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, ESMO, immunotherapy, ipilimumab, Radiotherapy, Uncategorized, vaccines|0 Comments

The Well Reviewed Guide to Advanced Prostate Cancer (A Survivor Perspective) Has Been Updated and is Now Available for a free Download

Somehow I have been negligent and not let people know that I have written and posted a major update of my “Guide to Advanced Prostate Cancer.” As in the past, it is available as a free download from the Malecare web site. Helping me to update the book was prostate cancer survivor Craig Pynn and [...]

By Malecare|2017-10-19T10:47:58-04:00September 30th, 2014|2nd line hormone therapy, abiraterone acetate, adjuvant therapy, ADT, Advanced Prostate Cancer, Alpha Emitting Radio Therapy, Alpharadin (radium-223), Androgan Receptor Inhibitor, Bio Chemical Recurrence, biomarkers, bisphosphonates, Bone Health, Bone Metastases, Bone Mineral Density, CAB, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Combination Therapy, Cross Resistance, Cryotherapy, CTCs, denosumab - Xgeva, Diet, Diet and Supplements, Drugs & Treatments, Early Access Program (EAP), Early/Expanded Access Programs, End-Of-Life, enzalutamide, estrogen patches, FDA, Financial, Firmagon (degarelix), General Information, genetics, HIFU, Hormone Therapy, Hot Flashes, How We Live, immunotherapy, Incontinence, inflammation, ipilimumab, ketoconazole, Medicare/Medicaid, mental health, Metastases, MRIs, NCI, neuroendocrine prostate cancer, neutropenia, Nilandron, oligometastic, On The Horizon, Our Caretakers, Pain, perineural invasion, peripheral neuropathy, Personal Experiences, prognostic tools, Prostate Ponderings, Prostvac, Provenge, PSA, PSADT, Quality of Life, radiation proctitis, radiopharmaceuticals, Radiotherapy, Research, Revlimid (lenalidomide), salvage therapy, statins, supplements, survival, survivorship, TAK700, teleconferences, Uncategorized, Understanding APC, vaccines, Vitamine D3, weight gain, Xgeva, XL184, Xofigo, Xtandi, Zometa, Zytiga|1 Comment

Long-term Survival of Extremely Advanced Prostate Cancer Patients Diagnosed with PSA over 500 ng/ml

It is generally believed that combination hormone therapy (ADT 2, 3 or 4) is superior to mono-therapy (with just one drug). With this in mind researchers investigated the survival of hormone-naïve prostate cancer survivors diagnosed with prostate-specific antigen (PSA) over 500 ng/ml. They extracted data of prostate cancer survivors from the Japan Study Group of [...]

By Malecare|2020-02-04T12:15:51-05:00September 22nd, 2014|ADT, Advanced Prostate Cancer, Combination Therapy, Drugs & Treatments, Hormone Therapy, PSA, survival, Uncategorized, Understanding APC|2 Comments

Efficacy of Combined Androgen Blockade with Zoledronic Acid *

It is known that Zoledronic acid (ZA) reduces the risk of developing skeletal-related events (SRE) which are caused by bone metastasis in prostate cancer (PCa). ZA also improves the quality of life (QOL). ZA has become a standard supportive therapy for men with prostate cancer who have bone metastasis. The big unknown is when should [...]

By Malecare|2017-10-19T10:48:05-04:00August 13th, 2014|ADT, Advanced Prostate Cancer, CAB, Combination Therapy, Drugs & Treatments, Uncategorized, Understanding APC|0 Comments

Can Chemotherapy (Docetaxel) Be Enhanced By Zoledronic Acid Pretreatment in Resistant Prostate Cancer Cells *

Docetaxel is the only globally approved first-line chemotherapy for the treatment of castrate resistant prostate cancer. Yhe universal truth is that all men taking docetaxel will become refractory to the treatment. Zoledronic acid (ZA) is the most commonly used member of nitrogen-containing bisphosphonate family. By itself it has anti-tumor activity, including in prostate cancer. In [...]

By Malecare|2014-08-05T14:08:36-04:00August 5th, 2014|Advanced Prostate Cancer, ASCO, bisphosphonates, Chemo Therapy, Chemo Therapy Failure, Combination Therapy, Drugs & Treatments, Research, Uncategorized, Understanding APC, Zometa|0 Comments

ASCO 2014: Combining Advanced Hormone Therapies (Zytiga & Xtandi) Shows Promise for Men with Advanced Prostate Cancer

In my continuing reports about interesting and pertinent information released at the ASCO 2014 meeting one abstract described a phase 2 trial combining an attack on androgens in metastatic prostate cancer resistant to initial hormone therapy. This proof of concept study showed that combining Enzalutamide (Xtandi) plus abiraterone (Zytiga) drove down testosterone levels and appeared [...]

By Malecare|2017-10-19T10:48:10-04:00June 5th, 2014|2nd line hormone therapy, abiraterone acetate, ADT, Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, enzalutamide, Uncategorized, Xtandi, Zytiga|1 Comment

The ASCO 2014 Game Changer – Early Chemotherapy for Some Men Extends Survival

I was asked if there was one item that was a real game changer at the American Society of Clinical Oncologists (ASCO) meeting for men with advanced prostate cancer. The answer is yes, at this meeting it was formally shown by a study that starting chemotherapy (docetaxel) along with androgen deprivation therapy (ADT) in some [...]

By Malecare|2014-06-03T10:23:15-04:00June 3rd, 2014|ADT, Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, Uncategorized, Understanding APC|4 Comments